Group items matching

in title, tags, annotations or url

The Department of Chemistry and Biochemistry at The University of Southern Mississippi is continuing its Summer Undergraduate Research Experience for undergraduates who will begin their senior year in the fall of each academic year. This program is designed to allow undergraduate students from other universities with little or no research experience to conduct graduate-level research on the USM campus in Hattiesburg under the direction of a faculty member in the Department during the summer of your current academic year. Fellowship recipients will receive a $4,500 stipend for the 10 week summer session and paid on-campus lodging. Supplemental travel funds are available for those traveling long distances. The program is intended for students with an interest in chemistry or biochemistry as a career. Students interested primarily in medical, pharmacy, dental or other pre-professional schools are encouraged to look to those schools for summer opportunities.

This two-day conference focuses on translational aspects of addiction research among chemists, biologists, and behavioral scientists. The diversity of participants and attendees at this meeting (undergraduate students to senior faculty, chemists to psychiatrists) provides a unique venue for cross-fertilization among different disciplines and in so doing promotes new and innovative approaches to medications development in addictions biology. The meeting provides a stimulating environment for young scientists who are strongly encouraged to present their work and interact with senior scientists.

The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for Administrative Supplements to NIGMS-funded R01, R37, P01, and U01 grants.  These funds are intended for the purchase of single pieces of equipment whose requested direct costs are between $50,000 and $250,000. Equipment in this price range is often difficult to purchase under the parent grant.  Two or more NIGMS grantees at the same institution with similar equipment needs are encouraged to submit separate requests (each between $50,000 and $250,000) that cross-reference each other.  It is expected that the amount of funds requested for such joint purchases will reflect the actual proportion of the time that the shared equipment would be used by each PI.  NIGMS encourages requests that reflect institutional commitment.

Bioequivalence studies that compare a reference formulation to an investigational formulation are typically conducted in healthy adult volunteers and occasionally are conducted in patients. Some populations have unique physical, biological, and physiological considerations that are not reflected by healthy volunteers or by the typical patient for whom a drug is indicated. Physicians have expressed concerns about generic drug substitution (especially for narrow therapeutic index drugs) in special patient populations whose experience with a drug may not be represented by those in whom bioequivalence studies are conducted. For instance, for products that do not have age-appropriate formulations (e.g., formulations do not differ by age of patient), the use of generic products under "off-label" practice patterns in special populations such as crushing or dissolving tablets in liquid for pediatric patients may influence their equivalence to brand name products. Special populations include, but are not limited to, pediatric patients, elderly patients who take multiple medications, women (particularly those who are pregnant), racial/ethnic minorities, and/or individuals with impaired kidney or liver function.

The National Institute on Drug Abuse (NIDA) intends to publish a series of Funding Opportunity Announcements (FOA) for Cooperative Agreements to solicit applications for a network of researchers collaborating across justice and community-based service settings to transform community-level responses to opioid misuse and opioid use disorder in justice-involved populations. Opioid misuse and opioid use disorder consequences exist at the intersection of health and justice systems. Improving the capacity of the justice system to respond to opioid crisis with evidence-based approaches that include the use of medications for OUD requires strong partnerships between justice systems and healthcare as well as other community based organizations. Supporting the development of these relationships and novel models of justice-healthcare and other community collaborations is a critical target in addressing the current opioid crisis. NIDA is interested in launching a network of investigators who can rapidly conduct research to address the opioid crisis in justice settings. A variety of research methods will be used, including clinical trials, implementation science research, policy evaluations and/or modeling approaches. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects. This FOA is expected to use a multicomponent cooperative agreement mechanism. The FOA is expected to be published in October 2018 with an expected application due date in December 2018.

NineSigma, representing SEIKAGAKU CORPORATION (http://www.seikagaku.co.jp/english/index.html  ), seeks a potential partner to expand medical applications of fermented chondroitin (FCH) and chemically sulfated fermented chondroitin (s-FCH) manufactured by the client.

The Howard Hughes Medical Institute (HHMI) in Chevy Chase, Maryland, is inviting applications for the third round of its Inclusive Excellence Initiative (IE3), which is designed to promote diversity and inclusion in science education. The program challenges colleges and universities to work with faculty to examine and change campus cultures so that a diverse group of students feel included in science. More than 1,400 institutions are eligible to compete, and HHMI expects to award grants to up to 30 more schools, with $1 million provided to each over five years.

The Alzheimer's Drug Discovery Foundation has issued a Request for Proposals for its Preclinical Drug Discovery program. Through the program, grants of up to $600,000 over two years will be awarded to promising preclinical drug discovery programs relevant to Alzheimer's disease, related dementias, and cognitive aging. Preclinical research funding priorities include high throughput screening, medicinal chemistry hit-to-lead development and optimization, in vitro and in vivo efficacy studies, ADME, toxicology, pharma-cokinetics and pharma-co-dynamics, and in vivo proof-of-concept with lead compounds and biologics. Program areas of particular interest include new chemical compounds for Alzheimer's disease, preclinical proof-of-concept, and re-purposing. With regards to potential drug targets, ADDF is interested in novel targets that include but are not limited to neuro-inflammation, protein degradation/autophagy, growth factor signaling, synaptic function/morphology, calcium regulation, energy utilization/mitochondria function, insulin sensitivity, epigenetics, ApoE function and cholesterol metabolism, vascular injury and the blood-brain barrier interface, cognitive enhancers, myelin changes, ischemia and oxidative stress, and tau-related toxicities. To be eligible, applicants must be academic investigators seeking to create and support innovative translational programs in academic medical centers and universities; biotechnology companies with programs dedicated to Alzheimer's disease translational development; and new biotechnology company spinouts or existing biotechnology companies that demonstrate a clear need for nonprofit funding. Funding is provided through program-related investments (PRIs) that require a return on investment based on scientific and/or business milestones.

The purpose of this initiative is to encourage research that investigates the role of epigenetic or non-coding RNA regulatory pathways in the development, maintenance, or treatment of chronic pain. Ultimately research in the area will provide foundational knowledge that can be exploited to develop novel and non-addictive pain medications or to develop biomarkers that predict chronic pain progression or treatment response.

The PREPARE program aims to develop programmable gene modulators for humans that can provide specific, effective, safe, and transient medical countermeasures and prophylaxes to combat chemical, biological, radiological, and/or nuclear (CBRN) threats.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate developmental research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research evaluating the effect of care planning on self-management of late effects of cancer therapy; adherence to medications, cancer screening, and health behavior guidelines; utilization of follow-up care; survivors' health and psychosocial outcomes. How organizational-level factors influence the implementation of care planning and its associated costs is also of interest. Specifically, the FOA aims to stimulate research that will: 1) develop and test metrics for evaluating the impact of survivorship care planning; 2) evaluate the impact of survivorship care planning on cancer survivors' morbidity, self-management and adherence to care recommendations, utilization of follow-up care; 3) evaluate effects of planning on systems outcomes, such as associated costs and impact on providers and organizations implementing the care planning; and 4) identify models and processes of care that promote effective survivorship care planning. The ultimate goal of this FOA is to generate a body of science that will inform the development and delivery of interventions that improve follow-up care for cancer survivors.

The Jane Coffin Childs Memorial Fund for Medical Research was established in 1937 for the purpose of supporting research into the causes and treatment of cancer. The fund has taken a broad approach to the study of cell growth and development, emphasizing the study of the basic biology and chemistry of the underlying processes, and increasingly has focused its resources on the funding of three-year postdoctoral fellowships, supporting fellows selected by its board of scientific advisers from among the best young scientists at what is often a critical stage in their careers. As a result, there have been more than sixteen hundred Jane Coffin Childs fellows doing basic cancer-related research in laboratories in North America, Europe, Japan, and Australia. To advance its mission, the JCC Fund is accepting applications for its fellowship program. The fund supports between twenty-five and thirty new three-year cancer research fellowships every year. The current fellowship stipend levels are $52,000 for year one; $52,500 for year two; and $53,000 for year three.

WHO CAN APPLY? I-Corps@Ohio funds will be offered on a competitive basis to teams of faculty researchers and graduate students developing institution-based technologies from Ohio colleges and universities. Under the supervision of business and entrepreneurial mentors, teams will develop market-driven value propositions and scalable business models around their technologies and attract follow on funding to support company formation and market entry. APPLICATION PROCESS The I-Corps@Ohio proposal submission process consists of five steps: 1. mandatory meeting with the appropriate TTO representative(s) at the PI's institution; 2. team selection of technology track (science and engineering or medtech); 3. registration of all team members in the online portal; 4. proposal submission; and 5. full team interview with I-Corps@Ohio program representatives. All teams are required to complete the online profile and submission questionnaire beginning October 23, 2019. Deadline to apply is January 15, 2019. The PI may complete this information or designate another member of the team as the lead member. Subsequent members of the team will be invited to join by the lead member through the application portal and must complete his or her profile. Every effort should be made to identify all team members prior to submitting the online proposal submission questionnaire. Additional team members may be added later. You will be asked to select from two tracks: Medtech Track: Teams will select Medtech Track if the subject technology is in the form of medical devices, diagnostics, medicines, vaccines, software, testing procedures and systems and is developed to solve a health/clinical problem and improve the quality of human life. Science and Engineering (S&E) Track: Teams will select S&E Track if the technology does not fit into the Medtech category.

Pre-release of the latest topics in the Air Force's SBIR and STTR Commercial Solutions Opening program, which include COVID-19 pandemic materials and manufacturing advances, human performance and medical response advances/solutions and information sciences' advances/solutions

The Ohio Department of Higher Education (ODHE) will make strategic investments to support expanded opportunities for students in Science, Technology, Engineering, Mathematics and Medical (STEMM) fields. The investments will directly impact the ability of the state of Ohio to educate and train students to meet Ohio's career and job opportunities today and tomorrow. Choose Ohio First provides scholarships to students in innovative academic programs developed by Ohio's two-year and four-year, public and private colleges and universities, along with their business partners. The scholarships connect students to work-based learning experiences and careers in STEMM fields in order to recruit and retain these students in Ohio. Choose Ohio First is part of a strategic effort to deepen Ohio's economic strength by increasing the talent pipeline for STEMM-related industries, including computer science, through degree and certificate completion.

The Blavatnik National Awards honor America's most innovative young faculty-rank scientists and engineers. These awards celebrate the past accomplishments and future potential of young faculty members working in the three disciplinary categories of Life Sciences, Physical Sciences & Engineering, and Chemistry. Every year, one Blavatnik National Awards Laureate in each disciplinary category will receive $250,000 in unrestricted funds, and additional nominees will be recognized as Finalists. Nominations are accepted from an invited group of research universities, independent research institutions, academic medical centers, and government laboratories from around the United States, as well as from the Awards' own Scientific Advisory Council, composed of renowned science and technology leaders. Miami University is an invited institution. If you are interested in being nominated, please contact Heather Johnston (johnsthb@MiamiOH.edu) in the Office of Research & Innovation.

The Cottrell Scholar Award (CSA) is available to early career faculty at US and Canadian research universities and primarily undergraduate institutions. Eligible applicants are tenure-track faculty who hold primary or courtesy appointments in chemistry, physics, or astronomy departments that offer bachelor's and/or graduate degrees in the applicant's discipline, For the 2020 proposal cycle, eligibility is limited to faculty members who started their first tenure-track appointment anytime in calendar year 2017. Accommodations are made for faculty who have taken maternity or paternity leave, or who have experienced medical conditions that prompted a tenure clock extension.

Awarded through the ACS Division of Medicinal Chemistry, the annual award is intended to recognize two current graduate students and/or postdoctoral researchers who have played a leading role in scientific discoveries that have enhanced the field of medicinal chemistry. The awardees will be invited to present an award address at the fall national meeting of the American Chemical Society and will receive a commemorative plaque and $3,500 honorarium.

This NOFO will build on previous PEPFAR support under the HHS/CDC HIV treatment program in Côte d'Ivoire (CI) to ensure continuity of comprehensive HIV/AIDS services to an existing pool of clients receiving HIV/AIDS care, support, and/or treatment. The program will also continue expanding access to HIV/AIDS services while building the capacity of national structures and contributing to sustainable service delivery within the health sector in CI. Specifically, it serves to increase capacity and sustainability of the response toward controlling the HIV/AIDS epidemic by initially providing support for HIV service delivery aligning with PEPFAR geographic and programmatic pivots by local indigenous organizations and ultimately providing technical assistance to the national Ministry of Health and Public Hygiene (MSHP) to sustain and expand comprehensive HIV prevention, care, and antiretroviral therapy (ART) programs. The recipient(s) will combine a facility and community-based strategy to support HIV/AIDS services. At the end of the 5-year project period, the recipient(s) should be able to collect and evaluate program data that demonstrates improved quality of HIV prevention, care, and treatment services in CI and to transition activities to MSHP and/or local organizations to sustain a basic HIV service package.